Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are excited to start the trial and prove that Barricaid is a superior alternative for patients suffering from symptomatic, herniated discs," said Greg Lambrecht, President and CEO of Intrinsic. "Because so very many patients undergo surgical treatment of herniated discs, we believe a large number of patients stand to benefit from the technology."

About the Barricaid® Prosthesis

Intrinsic's Barricaid is an anular closure device that enables surgeons to directly close the defect in the region of the herniation. Implanted between the anulus and the nucleus, the Barricaid creates a mechanical barrier, allowing the surgeon to leave more nucleus within the disc.

About Intrinsic Therapeutics, Inc.

Intrinsic Therapeutics, Inc., based in Woburn, MA, is a medical device company focused on developing innovative therapies that address the spine market's many unmet clinical needs. The company's first product, Barricaid, is a revolutionary spinal implant that was developed to treat patients undergoing surgery for herniated lumbar discs. For more information about Intrinsic Therapeutics, Inc., please visit Contacts:Noel Rolon, VP, Clinical and RegulatoryGreg Lambrecht, President and CEOIntrinsic Therapeutics, +1 781 932-0222

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... The recently published 32nd Annual Report ... reveals that in 2014, someone called a poison center about every 11 seconds. ... were human exposure cases. , The American Association of Poison Control Centers (AAPCC) ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... as their exclusive channel partner for the Nutraceutical Specialties products into oral solid ... US, effective immediately. , “We are pleased to announce our expanded distribution ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, ... Matrix Surgical Mesh technology for soft tissue repair in the US via Insightra’s ... long-term resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 ...
Breaking Medicine News(10 mins):